Study guide

7.3 Sleep-Related Hypoventilation & Obesity Hypoventilation Syndrome

Certification in Clinical Sleep Health CCSH

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & Sleep Physiology

1.1 CCSH Exam Overview & Clinical Scope 1.2 Sleep Architecture, Stages & Normal Cycles 1.3 Neurobiology & The Two-Process Model of Sleep

2 Chapter 2: Circadian Biology, Lifespan & Normal Variation

2.1 Circadian Biology & Melatonin Regulation 2.2 Sleep Across the Lifespan: Pediatric to Geriatric 2.3 Sex, Gender, Environment & Culture: Variations in Normal Sleep

3 Chapter 3: Abnormal Sleep: Classification, Prevalence & Consequences

3.1 Classification, Terminology, Prevalence & Acute vs. Chronic Sleep Disturbances 3.2 Short- and Long-Term Effects of Sleep Disruption, Deprivation & Restriction

4 Chapter 4: Comorbid Medical & Mental Health Conditions

4.1 Cardiopulmonary, Metabolic & Neurological Comorbidities 4.2 Mental Health Disorders, Substance Use & Sleep 4.3 Chronic Pain & Other Medical Conditions Affecting Sleep

5 Chapter 5: Clinical Assessment, Documentation & Medications

5.1 Validated Questionnaires & Screening Instruments 5.2 Comprehensive Sleep History & Physical Assessment 5.3 Quality of Life, Health Changes & Clinical Documentation 5.4 Medications, OTC Products, Supplements & Substances: Effects on Sleep

6 Chapter 6: Sleep Testing & Explaining Results

6.1 Diagnostic Sleep Testing Modalities 6.2 Split-Night and Titration Studies, PAP-NAP, Oximetry & Explaining Results

7 Chapter 7: Sleep-Related Breathing Disorders

7.1 Obstructive Sleep Apnea: Pathophysiology & Diagnosis 7.2 Central Sleep Apnea, Cheyne-Stokes & Emergent Apneas 7.3 Sleep-Related Hypoventilation & Obesity Hypoventilation Syndrome

8 Chapter 8: Positive Airway Pressure Therapy & Titration

8.1 Modes of PAP Therapy: CPAP, APAP, BiPAP & ASV 8.2 Interfaces, Humidification & Equipment Troubleshooting 8.3 Objective PAP Adherence Monitoring & Troubleshooting

9 Chapter 9: Non-PAP Treatments for Sleep Apnea

9.1 Oral Appliance Therapy: Indications, Candidacy & Side Effects 9.2 Surgical Interventions & Hypoglossal Nerve Stimulation 9.3 Positional Therapy & Lifestyle Modifications

10 Chapter 10: Insomnia & Circadian Rhythm Sleep-Wake Disorders

10.1 Chronic Insomnia: ICSD-3 Classification & Assessment 10.2 Cognitive Behavioral Therapy for Insomnia (CBT-I) Principles 10.3 Circadian Rhythm Sleep-Wake Disorders & Light Therapy

11 Chapter 11: Hypersomnias, Parasomnias & Movement Disorders

11.1 Central Disorders of Hypersomnolence 11.2 Parasomnias: NREM & REM Sleep Behavior Disorders 11.3 Sleep-Related Movement Disorders: RLS & PLMD

12 Chapter 12: Patient, Family & Community Education

12.1 Health Literacy, Plain Language & Teach-Back 12.2 Cultural Competency, Diversity of the Learner & Language Access 12.3 Readiness to Learn & Teaching Across Age, Development and Role 12.4 Learning Styles, Adult Learning Principles & Teaching Methods 12.5 Communication Barriers, Disabilities & Educating Families, Professionals and the Community

13 Chapter 13: Self-Management & Behavior Change

13.1 Motivational Interviewing & Overcoming Treatment Barriers 13.2 Sleep Hygiene Education Across Lifestyles and Settings 13.3 Self-Assessment & Self-Management Tools 13.4 Commercial Drivers, Transportation Regulations & Drowsy Driving

14 Chapter 14: Care Coordination, Guidelines, Telehealth & Ethics

14.1 Interdisciplinary Care Coordination & Patient Navigation 14.2 Chronic Disease Model, Care Plans & AASM Clinical Practice Guidelines 14.3 Telehealth Modalities & Remote Patient Monitoring 14.4 Ethics, Scope of Practice & Legal Standards

15 Chapter 15: Program Administration, Public Health & Safety

15.1 Building Collaborative Sleep Programs: Perioperative, Occupational, Outpatient & Support Models 15.2 Quality Improvement, Clinical Outcomes & Accreditation Standards 15.3 Sleep as a Public Health Issue: Community Outreach & Public Policy 15.4 Clinical Safety, Infection Control & Emergency Protocols

7.3 Sleep-Related Hypoventilation & Obesity Hypoventilation Syndrome

Key Takeaways Explain This Topic AI

Sleep-Related Hypoventilation is defined by sustained nocturnal hypercapnia (PaCO2 >55 mmHg for ≥10 minutes, or a rise of ≥10 mmHg to a value >50 mmHg for ≥10 minutes), monitored non-invasively via transcutaneous CO2 (tcCO2) or end-tidal CO2 (PetCO2).

Obesity Hypoventilation Syndrome (OHS) requires the clinical triad of obesity (BMI ≥30 kg/m²), daytime awake alveolar hypoventilation (arterial PaCO2 ≥45 mmHg at sea level), and the exclusion of alternative pulmonary, chest wall, or neuromuscular etiologies.

A daytime venous serum bicarbonate (HCO3⁻) threshold ≥27 mEq/L serves as a highly sensitive screening filter for chronic metabolic compensation, warranting confirmatory arterial blood gas analysis; OHS coexists with OSA in ~90% of cases.

In COPD-OSA overlap syndrome, REM hypoxemia and pulmonary hypertension are common, and oxygen alone is unsafe because it leaves the airway obstructed and can worsen CO2 retention.

Rapidly progressive neuromuscular disorders (e.g., ALS) cause selective nocturnal diaphragmatic failure during REM sleep; early non-invasive ventilation (NIV/BiPAP) is indicated based on orthopnea, awake PaCO2 ≥45 mmHg, FVC <50%, or MIP worse than -60 cmH2O.

Last updated: October 2026

7.3 Sleep-Related Hypoventilation & Obesity Hypoventilation Syndrome

Quick Answer: Sleep-Related Hypoventilation is characterized by sustained nocturnal alveolar hypoventilation, defined by the AASM as a PaCO 2 > 55 mmHg \text{PaCO}_2 > 55\text{ mmHg} PaCO 2 ​ > 55 mmHg for ≥ 10 \ge 10 ≥ 10 minutes or a sleep-related increase of ≥ 10 mmHg \ge 10\text{ mmHg} ≥ 10 mmHg to a level > 50 mmHg >50\text{ mmHg} > 50 mmHg for ≥ 10 \ge 10 ≥ 10 minutes. Obesity Hypoventilation Syndrome (OHS, historically Pickwickian syndrome) requires the clinical triad of obesity ( BMI ≥ 30 kg/m 2 \text{BMI} \ge 30\text{ kg/m}^2 BMI ≥ 30 kg/m 2 ), daytime awake alveolar hypoventilation (arterial PaCO 2 ≥ 45 mmHg \text{PaCO}_2 \ge 45\text{ mmHg} PaCO 2 ​ ≥ 45 mmHg at sea level), and the exclusion of alternative causes. A daytime venous serum bicarbonate threshold ≥ 27 mEq/L \ge 27\text{ mEq/L} ≥ 27 mEq/L serves as an optimal sensitive screening marker for chronic renal compensation. In COPD-OSA Overlap Syndrome, oxygen alone is hazardous because it leaves the airway obstructed and can worsen CO2 retention, risking acute-on-chronic hypercapnic respiratory failure; positive airway pressure (PAP) therapy is required.

While obstructive and central sleep apneas represent episodic, cyclic respiratory pauses, sleep-related hypoventilation disorders involve sustained, non-cyclical failure of alveolar gas exchange. For the Clinical Sleep Health Specialist (CCSH), recognizing hypoventilation pathophysiology, mastering non-invasive carbon dioxide monitoring, and navigating non-invasive ventilation (NIV) indications is vital for managing patients with severe multimorbidity.

Sleep-Related Hypoventilation: AASM Diagnostic Scoring & Carbon Dioxide Monitoring

During normal sleep in healthy individuals, alveolar ventilation decreases slightly due to reduced metabolic rate, decreased chemosensitivity, and increased upper airway resistance. This produces a benign, physiological rise in arterial PaCO 2 \text{PaCO}_2 PaCO 2 ​ of 2 to 8 mmHg 2\text{ to }8\text{ mmHg} 2 to 8 mmHg . In pathological hypoventilation, severe impairment in ventilatory drive, respiratory mechanics, or neuromuscular pumping capacity produces dangerous elevations in carbon dioxide.

AASM Polysomnographic Scoring Criteria for Sleep-Related Hypoventilation

According to the AASM Scoring Manual, sleep-related hypoventilation in adults is scored when either of the following criteria is met:

An arterial PaCO 2 \text{PaCO}_2 PaCO 2 ​ (or an approved surrogate) during sleep of > 55 mmHg >55\text{ mmHg} > 55 mmHg for at least 10 minutes ; OR

An increase in PaCO 2 \text{PaCO}_2 PaCO 2 ​ (or surrogate) during sleep of ≥ 10 mmHg \ge 10\text{ mmHg} ≥ 10 mmHg compared to an awake supine baseline value, to a value exceeding 50 mmHg 50\text{ mmHg} 50 mmHg for at least 10 minutes .

Non-Invasive Carbon Dioxide Monitoring Modalities

Continuous arterial blood gas (ABG) monitoring during sleep is technically impractical, painful, and disrupts sleep architecture. Clinical sleep medicine utilizes two non-invasive surrogates:

Feature / Metric Transcutaneous Carbon Dioxide ( tcCO 2 \text{tcCO}_2 tcCO 2 ​ ) End-Tidal Carbon Dioxide ( PetCO 2 \text{PetCO}_2 PetCO 2 ​ )

Measurement Principle Measures cutaneous gas diffusion via an electrochemical or optical sensor heated to 42 ∘ C to 44 ∘ C 42^{\circ}\text{C to } 44^{\circ}\text{C} 4 2 ∘ C to 4 4 ∘ C to induce local capillary arterialization. Measures carbon dioxide concentration at the end of expiration via nasal-oral cannula capnography.

Accuracy & Clinical Correlation High correlation with arterial PaCO 2 \text{PaCO}_2 PaCO 2 ​ in adult and pediatric sleep disorders; unaffected by mouth breathing or upper airway collapse. Reliable in intubated patients and healthy controls; frequently underestimates true PaCO 2 \text{PaCO}_2 PaCO 2 ​ in pulmonary disease.

Impact of V / Q V/Q V / Q Mismatch & PAP Unaffected by ventilation-perfusion ( V / Q V/Q V / Q ) mismatch or supplemental PAP airflow dilution. Severely compromised by dead-space ventilation, tachypnea, severe airflow obstruction, or high-flow PAP bias flow.

Technical Requirements & Risks Sensor site must be rotated every 2 to 4 hours 2\text{ to }4\text{ hours} 2 to 4 hours to prevent cutaneous thermal burns; requires 10 to 15 -minute 10\text{ to }15\text{-minute} 10 to 15 -minute initial equilibration. Prone to cannula clogging by nasal secretions; cannot measure alveolar plateau during mouth breathing or severe hypopnea.

Typical Use Preferred non-invasive surrogate in many labs for nocturnal hypoventilation and PAP titration in adults and children. Useful adjunct in pediatric PSG without lung disease; inadequate for quantitative titration in adult COPD or OHS.

Obesity Hypoventilation Syndrome (OHS / Pickwickian Syndrome)

Obesity Hypoventilation Syndrome (OHS) is a serious, life-threatening cardiometabolic and respiratory disorder defined by the following triad:

Obesity: Body Mass Index (BMI) ≥ 30 kg/m 2 \ge 30\text{ kg/m}^2 ≥ 30 kg/m 2 .

Daytime Awake Alveolar Hypoventilation: Arterial blood gas demonstrating an awake resting PaCO 2 ≥ 45 mmHg \text{PaCO}_2 \ge 45\text{ mmHg} PaCO 2 ​ ≥ 45 mmHg at sea level.

Exclusion of Alternative Explanations: Absence of severe underlying pulmonary parenchymal disease (e.g., severe COPD with FEV 1 < 50 % \text{FEV}_1 < 50\% FEV 1 ​ < 50% ), severe chest wall deformities (e.g., advanced kyphoscoliosis), neuromuscular weakness (e.g., ALS), or severe untreated hypothyroidism.

Pathophysiological Triad Driving OHS

OHS is not simply severe OSA in an obese individual; it represents a comprehensive failure of respiratory homeostasis driven by three interrelated mechanisms:

Altered Respiratory Mechanics & Load: Massive deposition of adipose tissue on the thoracic wall and within the visceral abdominal cavity markedly decreases chest wall compliance. This severely reduces Functional Residual Capacity (FRC) and Expiratory Reserve Volume (ERV), forcing breathing into closing capacities and inducing extensive microatelectasis and ventilation-perfusion ( V / Q V/Q V / Q ) mismatch. The mechanical work of breathing in OHS is increased up to three-fold compared to normal-weight controls.

Blunted Central Chemosensitivity: Patients with OHS demonstrate severely blunted central hypercapnic and peripheral hypoxic ventilatory responses. Instead of mounting a compensatory hyperventilatory response to clear daytime carbon dioxide loads, the respiratory centers tolerate hypercapnia.

Central Leptin Resistance: Leptin is a hormone produced by adipocytes that acts centrally in the hypothalamus and nucleus tractus solitarius as a potent neurochemical respiratory stimulant . In severe obesity, patients exhibit profound central leptin resistance. Despite markedly elevated circulating leptin levels, the brainstem fails to respond, extinguishing leptin's physiological stimulation of alveolar ventilation.

  • Screening & Clinical Coexistence with OSA Patient with Obesity (BMI ≥30 kg/m²) Evaluated for Sleep Disorders
  • │
  • ▼
  • Screen Venous Serum Bicarbonate (HCO3⁻)
  • │
  • ┌────────────┴────────────┐
  • ▼ ▼
  • HCO3⁻ < 27 mEq/L HCO3⁻ ≥ 27 mEq/L
  • │ │
  • ▼ ▼
  • OHS Virtually Excluded Strong Clinical Suspicion
  • (Negative Predictive Value) │
  • ▼
  • Confirm via Daytime Awake
  • Arterial Blood Gas (ABG)
  • │
  • ┌────────────┴────────────┐
  • ▼ ▼
  • PaCO2 < 45 mmHg PaCO2 ≥ 45 mmHg
  • │ │
  • ▼ ▼
  • Normal Awake Confirmed Daytime
  • Ventilation Alveolar Hypoventilation
  • │
  • ▼
  • Rule out severe COPD,
  • NMD, or kyphoscoliosis
  • │
  • ▼
  • Diagnostic Triad for
  • OHS Confirmed
  • The Venous Bicarbonate Screening Algorithm

In chronic respiratory acidosis, the kidneys retain bicarbonate ( HCO 3 − \text{HCO}_3^- HCO 3 − ​ ) over 48 to 72 hours 48\text{ to }72\text{ hours} 48 to 72 hours to compensate and restore physiological arterial pH toward normal. A routine daytime venous serum bicarbonate threshold ≥ 27 mEq/L \ge 27\text{ mEq/L} ≥ 27 mEq/L serves as an exceptionally sensitive screening cutoff:

Sensitivity: high (roughly 85–92% in published cohorts);

Negative predictive value: very high when pretest probability is low to moderate, which is why the 2019 American Thoracic Society OHS guideline uses a bicarbonate below 27 mmol/L to make OHS unlikely in that group.

Clinical Rule: A venous bicarbonate < 27 mEq/L <27\text{ mEq/L} < 27 mEq/L makes OHS unlikely in stable outpatients with low-to-moderate suspicion, sparing many patients an arterial puncture. Conversely, a bicarbonate ≥ 27 mEq/L \ge 27\text{ mEq/L} ≥ 27 mEq/L warrants confirmatory arterial blood gas sampling.

Coexistence with Obstructive Sleep Apnea

∼ 90 % \sim 90\% ∼ 90% of OHS Patients: Have coexisting Obstructive Sleep Apnea , with the vast majority presenting with severe disease ( AHI ≥ 30 events/hour \text{AHI} \ge 30\text{ events/hour} AHI ≥ 30 events/hour ). During repetitive obstructive events, carbon dioxide loads accumulate; impaired daytime chemosensitivity prevents offloading, creating chronic awake hypercapnia.

∼ 10 % \sim 10\% ∼ 10% of OHS Patients: Exhibit isolated sleep-related hypoventilation without significant cyclic obstructive events, demonstrating sustained nocturnal hypoxemia and hypercapnia across sleep stages.

Cardiovascular & End-Organ Consequences

Untreated OHS carries catastrophic morbidity: up to 50 % 50\% 50% of patients have severe pulmonary hypertension , right ventricular hypertrophy, and cor pulmonale. Hospitalization rates for acute-on-chronic hypercapnic respiratory failure requiring ICU admission and mechanical intubation are exceptionally high.

COPD-OSA Overlap Syndrome: The Synergistic Threat

Overlap Syndrome refers specifically to the coexistence of Chronic Obstructive Pulmonary Disease (COPD) and Obstructive Sleep Apnea (OSA) in the same patient. Approximately 10 % 10\% 10% to 15 % 15\% 15% of patients with COPD also suffer from OSA.

Synergistic Pathophysiology & The "Blue Bloater" Phenotype

The combination of lower airway obstruction (loss of elastic recoil, air trapping, and ventilation-perfusion mismatch) and upper airway pharyngeal collapsibility produces severe, multiplicative morbidity:

Disproportionate REM Hypoxemia: In REM sleep, physiological atonia paralyzes the intercostal and accessory respiratory muscles. In COPD, the diaphragm is already flattened and mechanically disadvantaged by hyperinflation. When REM atonia eliminates intercostal assistance, alveolar ventilation collapses, provoking profound, sustained nocturnal desaturations out of proportion to daytime spirometry.

Multiplicative Cardiovascular Risk: Overlap patients exhibit markedly higher rates of pulmonary hypertension, right heart failure, cardiac arrhythmias, and all-cause mortality than patients with either COPD or OSA alone at similar levels of daytime impairment.

The Critical Danger of Isolated Oxygen Monotherapy

Warning

In patients with Overlap Syndrome, administering isolated supplemental oxygen monotherapy without positive airway pressure (PAP) is dangerous. Oxygen therapy does not relieve mechanical pharyngeal collapse. Furthermore, in chronically hypercapnic patients, uncontrolled high-flow oxygen can worsen carbon dioxide retention (through ventilation-perfusion changes, the Haldane effect and reduced ventilatory drive), leading to respiratory acidosis and, in severe cases, hypercapnic coma.

Therapy Principle: First-line therapy for Overlap Syndrome is PAP therapy (CPAP or Bilevel PAP) to splint the upper airway open, unload respiratory muscles, and improve alveolar ventilation. Supplemental oxygen should only be entrained into the PAP circuit if nocturnal hypoxemia persists despite adequate airway patency and ventilation.

Neuromuscular Disease & Chest Wall Hypoventilation

Disorders such as Amyotrophic Lateral Sclerosis (ALS) , Duchenne Muscular Dystrophy, Myasthenia Gravis, Spinal Muscular Atrophy, Post-Polio Syndrome, and severe Kyphoscoliosis cause progressive respiratory muscle weakness.

Pathophysiological Progression

Nocturnal hypoventilation is almost universally the initial clinical manifestation of respiratory failure in neuromuscular disease, occurring long before daytime hypercapnia appears on blood gas testing. Clinical clues include morning headaches (from nocturnal cerebral vasodilation secondary to hypercapnia), unrefreshing sleep, daytime hypersomnolence, orthopnea, and paradoxical inward abdominal movement during inspiration.

Vulnerability of REM Sleep

During REM sleep, somatic motor inhibition abolishes intercostal and accessory muscle tone, leaving ventilation dependent solely on the diaphragm. In patients with bilateral diaphragmatic weakness, tidal volume drops precipitously during REM, triggering severe hypoventilation, hypercapnia, and dangerous arterial oxygen desaturations.

Indications for Non-Invasive Ventilation (NIV) in Progressive NMD

Consensus guidelines recommend initiating Non-Invasive Ventilation (Bilevel PAP with a backup rate or dedicated home mechanical ventilation) when a patient with progressive neuromuscular disease exhibits clinical symptoms of respiratory muscle fatigue (such as orthopnea, morning headaches, or unrefreshing sleep) AND meets at least one of the following objective physiological criteria:

Daytime Awake Arterial PaCO 2 ≥ 45 mmHg \text{PaCO}_2 \ge 45\text{ mmHg} PaCO 2 ​ ≥ 45 mmHg ;

Nocturnal Desaturation: Nocturnal pulse oximetry showing SpO 2 ≤ 88 % \text{SpO}_2 \le 88\% SpO 2 ​ ≤ 88% for at least 5 continuous minutes ;

Forced Vital Capacity (FVC) < 50 % < 50\% < 50% of predicted (or a drop in FVC of > 20 % >20\% > 20% when transitioning from seated to supine posture, indicating severe diaphragmatic weakness);

Maximal Inspiratory Pressure (MIP / P I max P_{I\text{max}} P I max ​ ) worse than − 60 cmH 2 O -60\text{ cmH}_2\text{O} − 60 cmH 2 ​ O (less negative than − 60 cmH 2 O -60\text{ cmH}_2\text{O} − 60 cmH 2 ​ O , such as − 40 cmH 2 O -40\text{ cmH}_2\text{O} − 40 cmH 2 ​ O ).

In ALS and other progressive neuromuscular disorders, timely initiation of NIV has been proven to significantly prolong survival, slow the decline of pulmonary function, and preserve neurocognitive quality of life.

Comparison of Sleep-Related Hypoventilation Syndromes

Hypoventilation Syndrome Primary Etiology & Pathogenesis Diagnostic Biomarkers & Testing Criteria Nocturnal Polysomnographic Profile First-Line Therapeutic Modalities

Obesity Hypoventilation Syndrome (OHS) Extreme obesity; reduced chest wall compliance; central leptin resistance; blunted CO 2 \text{CO}_2 CO 2 ​ chemosensitivity. BMI ≥ 30 kg/m 2 \text{BMI} \ge 30\text{ kg/m}^2 BMI ≥ 30 kg/m 2 ; daytime PaCO 2 ≥ 45 mmHg \text{PaCO}_2 \ge 45\text{ mmHg} PaCO 2 ​ ≥ 45 mmHg ; venous HCO 3 − ≥ 27 mEq/L \text{HCO}_3^- \ge 27\text{ mEq/L} HCO 3 − ​ ≥ 27 mEq/L (screening). Sustained nocturnal hypoventilation; coexists with severe OSA in ∼ 90 % \sim 90\% ∼ 90% . CPAP (if coexisting severe OSA); Bilevel PAP (BPAP-S/T); aggressive weight reduction and bariatric referral.

COPD-OSA Overlap Syndrome Coexisting bronchial airflow limitation (COPD) and pharyngeal collapsibility (OSA). Spirometry confirming FEV 1 / FVC < 0.70 \text{FEV}_1 / \text{FVC} < 0.70 FEV 1 ​ / FVC < 0.70 ; PSG confirming AHI ≥ 5 /hr \text{AHI} \ge 5\text{ /hr} AHI ≥ 5 /hr . Severe, prolonged REM oxygen desaturation out of proportion to daytime impairment. CPAP or Bilevel PAP; entrained supplemental oxygen only after resolving obstruction; bronchodilators.

Neuromuscular Hypoventilation (ALS / NMD) Diaphragmatic and accessory respiratory muscle weakness; somatic REM muscle atonia. Awake PaCO 2 ≥ 45 mmHg \text{PaCO}_2 \ge 45\text{ mmHg} PaCO 2 ​ ≥ 45 mmHg ; FVC < 50 % \text{FVC} < 50\% FVC < 50% ; MIP > − 60 cmH 2 O \text{MIP} > -60\text{ cmH}_2\text{O} MIP > − 60 cmH 2 ​ O ; supine FVC drop > 20 % >20\% > 20% . Severe hypoventilation isolated initially to REM sleep; preserved airway caliber. Bilevel PAP with mandatory backup rate (BPAP-ST); home mechanical volume ventilation; cough assist.

Chest Wall Deformity (Kyphoscoliosis) Severe thoracic spinal curvature ( > 70 ∘ to 100 ∘ >70^{\circ}\text{ to }100^{\circ} > 7 0 ∘ to 10 0 ∘ Cobb angle); restrictive ventilatory defect. Severe restrictive spirometry (low TLC and FVC); elevated awake PaCO 2 \text{PaCO}_2 PaCO 2 ​ . Nocturnal alveolar hypoventilation; low lung volume rapid shallow breathing. Non-invasive positive pressure ventilation (NIV); nocturnal ventilatory support.